TR^{*}POD

TRIPOD Checklist: Prediction Model Development and Validation

Title 1 D/V Identify the study as developing and/or validating a multivariable pradiction model, the 1 Abstract 2 D/V Provide a summary of objectives, study design, setting, participants, sample size, relations, and subjectives, study design, setting, and conclusions. 7 Introduction Explain the medical context (including whether diagnostic or prognostic) and rationale availing models. 8 and objectives 3a D/V Explain the medical context (including whether the study describes the development or validation of the model or both. 8 Method	Section/Topic	Item		Checklist Item	Page
Abstract 2 D _V Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical markies, includian and conclusions 7 Introduction	Title and abstract	1	D;V		1
Introduction Specify the objectives Specify the objective objective Specify the objective objective Specify the objective objective Specify the objective Specify the objective Specify the objective Specify t	Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size,	7
Background and objectives 3b D:V. for developing or validating the multivariable prediction model, including references to existing models. 8 Methods	Introduction				I
and objectives 3b Dr.V. Specify the objectives, including whether the study describes the development or validation of the model or both. 8 Methods 4a Dr.V. Specify the development and validation data sets, if applicable, and the model or both. 9 Participants 5a Dr.V. Specify the key study datas, including start of accrual; end d accrual; and d accrual; and a carcual; and a carcual; and d accrual; and accrual; and d accrual; and d accrual; and d accrual;	Background	3a	D;V	for developing or validating the multivariable prediction model, including references to	8
Methods Automa is a second of the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable. 9 Participants 5a D/V. Specify the key study dates, including start of accrual; end of accrual; and if applicable. 9 Participants 5a D/V. Specify the key study dates, including start of accrual; end of accrual; and if applicable. 9 Outcome 6a D/V. Describe diplikity criteria for participants. 9 Outcome 6a D/V. Give details of reatments received, if relevant. NA Outcome 6a D/V. Clearly define all predictors used in developing or validating the multivariable predictor 9 Predictors 7a D/V. Clearly define all predictors used in developing or validating the multivariable predictor 9.10 Sample size 8 D/V. Explain how the study size was arrived at. 9 Statistical analysis 100 D Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method. 11.12 Statistical analysis 100 D Specify type of modd		3b	D;V	Specify the objectives, including whether the study describes the development or	8
Source of data Image: the set of the development and validation data sets; if applicable, applicable, applicable, if applicable,	Methods				
Hash Diversity Specify key elements of the study setting (e.g., primary care, secondary care, general) 9 Participants 5a D; V Describe eligibility criteria for participants. 9 Social Version 5b D; V Describe eligibility criteria for participants. 9 Outcome 6a D; V Clearly define the outcome to be predicted. 10 Predictors 7a D; V Report any actions to blind assessment of the outcome to be predicted. 10 Sample size 8 D; V Report any actions to blind assessment of predictors for the outcome and other predictors. 9 Missing data 9 D; V Describe how missing data were handled in the analyses. 11,12 Statistical analysis 10a D Describe how missing data were handled in the analyses. 11,12 Statistical analysis 10b D Describe how missing data were handled in the analyses. 111,12 Statistical analysis 10b D Specify type of model, all model-building procedures (including any predictor selection). 111,12 Statistical analysis 10b V Describe how the pre	Source of data	4a	D;V	data), separately for the development and validation data sets, if applicable.	9
Participants 36 D-V population) including number and location of centres. 9 5b D-V Describe eligibility criteria for participants. 9 Cutcome 6a D-V Cive details of treatments received, if relevant. NA Outcome 6a D-V Civeard yelfne the outcome that is predicted by the prediction model, including how and when they were measured. 10 Predictors 7a D.V Report any actions to blind assessment of the outcome to be predicted. 10 Sample size 8 D-V Describe how missing data were handled (e g., complete-case analysis, single) 9 Missing data 9 D-V Describe how mesh gradied (e g., complete-case analysis, single) 9 Statistical analysis 10b D Describe how find corris were handled in the analyses. 11,12 10c V For validation, describe how the predictions were calculated. 11,12 10c V For validation (acsribe how the predictions were calculated. 11,12 10d D.V Describe any model updating (a.g., recalibration) arising from the validation, if done. NA Nak g		4b	D;V	end of follow-up.	9
Sc. D/V Give details of treatments received, if relevant. NA Outcome 6a D/V Clearly define the outcome that is predicted by the prediction model, including how and the predictors may actions to bind assessment of the outcome to be predicted. 10 Predictors 7a D;V Clearly define all predictors used in developing or validating the multivariable predictor. 9,10 Sample size 8 D;V Explain how the study size was arrived at. 9 Sample size 8 D;V Explain how the study size was arrived at. 9 Missing data 9 D;V Explain how the study size was arrived at. 9 Statistical analysis 10a D Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation, with etable or any imputation method. 11,12 10b D Specify type of model, all model-building procedures (including any predictors selection), and method for internal validation. 11,12 10c V For validation, describe how the predictors. 11,12 10d D;V Specify type of model, all model-building procedures (including the number of participants multiple models. 11,112 1	Participants			population) including number and location of centres.	
Outcome 6a D,V Clearly define the outcome that is predicted by the prediction model, including how and when assessed. 10 Predictors 7a D,V Clearly define alt predictors used in developing or validating the multivariable prediction model, including how and when they were measured. 10 Sample size 8 D/V Report any actions to blind assessment of predictors for the outcome and other predictors. 9 Missing data 9 D,V Describe how missing data were handled (e.g., complete-case analysis, single predictors. 9 Statistical analysis 10a D Describe how predictors were handled in the analyses. 11,12 Statistical analysis 10c V For validation, describe how the study size was arrived at. 11,12 Statistical analysis 10c V For validation, describe how the predictors. 11,12 No Specify type of model, all model-building procedures (including any predictor selection). 11,12 10d D;V Specify all measures used to assess model performance and, if relevant, to compare multiple models. 112 11 D;V Provide details on how risk groups were created, if done. NA Restorups			,		
Predictors Ta D ₁ V Clearly define all predictors used in developing or validating the multivariable prediction 9,10 Sample size 8 D ₁ V Report any actions to blind assessment of predictors for the outcome and other predictors. 9 Missing data 9 D ₁ V Explain how the study size was arrived at. 9 Missing data 9 D ₁ V Explain how the study size was arrived at. 9 Missing data 9 D ₁ V Explain how the study size was arrived at. 9 Statistical analysis 10a D Describe how predictors were handled in the analyses. 11.12 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. 11.12 11.12 10c V For validation, dentry hy or differences from the validation. NA Risk groups 11 D ₁ V Provide details on nov risk groups were created, if done. NA Development 12 V For validation, identify any differences from the evelopment data in setting, eligibility 11 Nodel 13a D ₁ V Winth witho	Outcome		ŕ	Clearly define the outcome that is predicted by the prediction model, including how and	
Predictors 7a U/V model, including how and when they were measured. 9.10 Sample size 8 D/V Report any actions to bind assessment of predictors for the outcome and other predictors. 10 Sample size 8 D/V Explain how the study size was arrived at. 9 Missing data 9 D/V Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method. 11,12 Statistical analysis 10a D Describe how predictors were handled in the analyses. 11,112 Itod D/V Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. 11,112 Itod D/V Specify all measures used to assess model performance and, if relevant, to compare to the validation identify any differences from the evalidation, if done. NA Development 12 V For validation, demand predictors. 13 Not predictors and outcome, and predictors and outcome, and predictor and outcome. 13 13 14 D/V Provide details on how risk groups were created, if done. NA 14 Statistical		6b	D;V		10
Tb D:V Report any actions to bind assessment of predictors for the outcome and other predictors. 10 Sample size 8 D:V Explain how the study size was arrived at. 9 Missing data 9 D.V Describe how missing data were handled (e.g., complete-case analysis, single 9 Statistical analysis 10a D Describe how predictors were handled in the analyses. 111,12 Statistical analysis 10b D Specify type of model, all model-building procedures (including any predictor selection). 111,11,12 Statistical analysis 10c V For validation, describe how the predictions were calculated. 111,12 Ide V For validation, describe how method was ever careated, if done. NA Resultar 12 V For validation, identify any differences from the development data in setting, eligibility 11 Resultar 13a D.V Wide data on how risk groups were created, if done. NA Participants 13a D.V Wide data on the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. 13a Porticipants 13a D.V	Predictors	7a	D;V	model, including how and when they were measured.	9,10
Missing data 9 D;v Describe how missing data were handled (e.g., complete-case analysis, single 9 Statistical analysis methods 10a D Describe how predictors were handled in the analyses. 111,12 Statistical analysis methods 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. 111,12 10c V For validation, describe how the predictions were calculated. 111,12 10d D;V Specify type of model and method for internal validation. 111,12 10d D;V For validation, describe how the predictions were calculated. 111,12 10d D;V Provide details on how risk groups were created, if done. NA Development vs. validation 12 V For validation, identify any differences from the development data in setting, eligibility 11 Ns. validation 12 V Criteria, outcome, and predictors. 13 13 13 Participants 13a D;V Describe the flow of participants through the study, including the number of participants with missing data for predictors and outcome. 13 13				predictors.	
Institution 9 U, v imputation, multiple imputation) with details of any imputation method. 9 Statistical analysis 10a D Describe how predictors were handled in the analyses. 111,12 Statistical analysis 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. 111,12 10c V For validation, describe how the predictions were calculated. 111,12 10d D:V Expectify all measures used to assess model performance and, if relevant, to compare multiple models. 12 10e V Por validation, idex cribs how the predictions were calculated. NA Risk groups 11 D;V Provide details on how risk groups were created, if done. NA Bevelopment vs. validation 12 V For validation, idex for the outcome and, if applicable, a summary of the follow-up time. A 13 Besults D:v Weith and without the outcome and, if applicable, a summary of the follow-up time. A 13 13a D;V V For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome). 13 <tr< td=""><td></td><td></td><td>-</td><td></td><td></td></tr<>			-		
Statistical analysis methods 10b D Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation. 11,12 10c V For validation, describe how the predictions were calculated. 111,12 10d D;V Specify all measures used to assess model performance and, if relevant, to compare multiple models. 112 10e V Describe any model updating (e.g., recalibration) arising from the validation, if done. NA Development vs. validation 12 V For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors. NA Participants 13a D;V Provide details on how risk groups were created. if done. NA Participants 13a D;V V For validation, identify any differences from the development data in setting, eligibility validation may be helpfut. 13 Participants 13a D;V V Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for important variables (demographics, predictors and outcome. 13 Model D Speciff the number of participants and outcome events in each analysis.<	Missing data			imputation, multiple imputation) with details of any imputation method.	
Statistical analysis methods 100 U and method for internal validation. 11,12 analysis methods 10c V For validation, describe how the predictions were calculated. 11,12 methods 10d D;V Specify all measures used to assess model performance and, if relevant, to compare multiple models. 12 10e V Pescribe any model updating (e.g., recalibration) arising from the validation, if done. NA Development 12 V For validation, identify any differences from the development data in setting, eligibility 11 Vs. validation 12 V For validation, identify any differences from the development data in setting, eligibility 11 Ns. validation 13a D;V Describe the flow of participants through the study, including the number of participants 13 Participants 13b D;V Describe the characteristics of the participants (basic demographics, clinical features, available predictors, including the number of participants with missing data for predictors and outcome. 13 Model 14a D Specify the number of participants and outcome. 13 Model 15b D Explain how to the use the predicti	analysis			Specify type of model, all model-building procedures (including any predictor selection),	
methods 10d D;V Specify all measures used to assess model performance and, if relevant, to compare multiple models. 12 10e V Describe any model updating (e.g., recalibration) arising from the validation, if done. NA Risk groups 11 D;V Provide details on how risk groups were created, if done. NA Development vs. validation 12 V For validation, identify any differences from the development data in setting, eligibility 11 Results 13a D;V Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A available predictors, including the number of participants (basic demographics, clinical features, available predictors, including the number of participants with missing data for validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome). 13 Model 14a D Specify the number of participants and outcome each analysis. 13 Model 15a D Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point). 13 Model 15a D Explain how to the use the prediction model.				and method for internal validation.	
10e V Describe any model updating (e.g., recalibration) arising from the validation, if done. NA Risk groups 11 D/V Provide details on how risk groups were created, if done. NA Development vs. validation 12 V For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors. 11 Results 13a D;V Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. 13 Participants 13b D;V Describe the characteristics of the participants (basic demographics, clinical features, available predictors and outcome. 13 Model development 14a D Specify the number of participants and outcome events in each analysis. 13 Model gerformance 15a D For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome). 13 Model gerformance 15a D Explain how to the use the prediction model. 13 Model gerformance 16 D;V Report performance measures (with Cls) for the predictin model. 13				Specify all measures used to assess model performance and, if relevant, to compare	
Risk groups 11 D;V Provide details on how risk groups were created, if done. NA Development vs. validation 12 V For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors. 11 Results		10e	V		NA
vs. validation 12 V criteria, outcome, and predictors. 11 Results Participants 13a D;V Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. 13 Participants 13b D;V Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome. 13 Model 14a D Specify the number of participants and outcome events in each analysis. 13 Model 14b D Specify the number of participants and outcome events in each analysis. 13 Model 15a D Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept to baseline survival at a given time point). 13 Model 16 D;V Report performance measures (with Cls) for the prediction model. 13 Model-updating 17 V If done, report the results from any model updating (i.e., model specification, model performance). 14 Interpretation 18 D;V Discuss an			D;V	Provide details on how risk groups were created, if done.	NA
Participants 13a D;V Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. 13 Participants 13b D;V Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome. 13 Model 13a D;V For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome). 13 Model 14a D Specify the number of participants and outcome events in each analysis. 13 Model 14b D Specify the number of participants and outcome events in each analysis. 13 Model 15a D Present the full prediction model to allow predictions for individuals (i.e., all regression outcome). 13 Model 15b D Explain how to the use the prediction model. 13 Model-updating 17 V If done, report the results from any model updating (i.e., model specification, model 14 Model-updating 17 V If done, report the results from any model updating (i.e.,	vs. validation	12	V		11
Participants 13b D;V Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome. 13 13c V For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome). 13 Model development 14a D Specify the number of participants and outcome events in each analysis. 13 Model development 14b D Specify the number of participants and outcome events in each analysis. 13 Model development 15a D Present the full prediction model to allow predictions for individuals (i.e., all regression outcome. 13 Model specification 15b D Explain how to the use the prediction model. 13 Model performance 16 D;V Report performance measures (with Cls) for the prediction model. 13 Model-updating 17 V If done, report the results from any model updating (i.e., model specification, model NA Initiations 18 D;V Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data). 14		13a	D;V		13
13cVFor validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).13Model development14aDSpecify the number of participants and outcome events in each analysis.13Model development14bDIf done, report the unadjusted association between each candidate predictor and outcome.NAModel specification15aDPresent the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).13Model performance16D;VReport performance measures (with Cls) for the prediction model.13Model-updating performance17VIf done, report the results from any model updating (i.e., model specification, modelNAModel-updating lnterpretation18D;VDiscuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).14Interpretation19aVGive an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.14Implications supplementary information20D;VDiscuss the potential clinical use of the model and implications for future research.14Umplications results20D;VProvide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.13		13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features,	13
Model development14aDSpecify the number of participants and outcome events in each analysis.13Model development14bDIf done, report the unadjusted association between each candidate predictor and outcome.NAModel specification15aDPresent the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).13Model performance16D;VReport performance measures (with CIs) for the prediction model.13Model-updating performance17VIf done, report the results from any model updating (i.e., model specification, model performance).NADiscussion18D;VDiscuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).14Interpretation19aVFor validation, discuss the results with reference to performance in the development data, and any other validation data.14Implications20D;VDiscuss the potential clinical use of the model and implications for future research.14Implications20D;VDiscus the potential clinical use of the model and implications for future research.14ModelD;VProvide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.13		10-			10
Model development14bDIf done, report the unadjusted association between each candidate predictor and outcome.NAModel specification15aDPresent the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).13Model performance16D;VReport performance measures (with CIs) for the prediction model.13Model-updating17VIf done, report the results from any model updating (i.e., model specification, model performance).NADiscussionIf done, report the results from any model updating (i.e., model specification, model performance).NADiscussionIf a D;VDiscuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).14Interpretation19aVFor validation, discuss the results with reference to performance in the development data, and any other validation data.14Implications20D;VGive an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.14Implications20D;VDiscuss the potential clinical use of the model and implications for future research.14Other information21D;VProvide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.13					
Model specification15aDPresent the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).13Model performance16D;VReport performance measures (with Cls) for the prediction model.13Model-updating performance17VReport performance measures (with Cls) for the prediction model.13Model-updating bertormance17VIf done, report the results from any model updating (i.e., model specification, modelNADiscussionImage: comparison of the study (such as nonrepresentative sample, few events per predictor, missing data).14Interpretation19aVDiscuss the results with reference to performance in the development data, and any other validation data.14Implications20D;VDiscuss the pretion of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.14Supplementary information21D;VProvide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.13				If done, report the unadjusted association between each candidate predictor and	
specification15bDExplain how to the use the prediction model.13Model performance16D;VReport performance measures (with CIs) for the prediction model.13Model-updating17VIf done, report the results from any model updating (i.e., model specification, modelNADiscussionIf done, report the results from any model updating (i.e., model specification, modelNALimitations18D;VDiscuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).14Interpretation19aVFor validation, discuss the results with reference to performance in the development data, and any other validation data.14Implications20D;VDiscuss the potential clinical use of the model and implications for future research.14Other information21D;VProvide information about the availability of supplementary resources, such as study 		15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression	13
performance16D;VReport performance measures (with Cis) for the prediction model.13Model-updating17VIf done, report the results from any model updating (i.e., model specification, modelNADiscussion18D;VDiscuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).14Interpretation19aVFor validation, discuss the results with reference to performance in the development data, and any other validation data.14Interpretations20D;VGive an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.14Other information21D;VProvide information about the availability of supplementary protocol, Web calculator, and data sets.13		15b	D		13
Model-updating 17 V performance). NA Discussion 18 D;V Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data). 14 Interpretation 19a V For validation, discuss the results with reference to performance in the development data, and any other validation data. 14 Interpretation 19b D;V Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence. 14 Implications 20 D;V Discuss the potential clinical use of the model and implications for future research. 14 Other information 21 D;V Provide information about the availability of supplementary information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. 13		16	D;V		13
Limitations 18 D;V Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data). 14 Interpretation 19a V For validation, discuss the results with reference to performance in the development data, and any other validation data. 14 19b D;V Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence. 14 Implications 20 D;V Discuss the potential clinical use of the model and implications for future research. 14 Other information 21 D;V Provide information about the availability of supplementary information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. 13		17	V		NA
Limitations 18 D,V predictor, missing data). 14 Interpretation 19a V For validation, discuss the results with reference to performance in the development data, and any other validation data. 14 19b D;V Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence. 14 Implications 20 D;V Discuss the potential clinical use of the model and implications for future research. 14 Other information 21 D;V Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. 13	Discussion				1
Interpretation 19a V data, and any other validation data. 14 19b D;V Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence. 14 Implications 20 D;V Discuss the potential clinical use of the model and implications for future research. 14 Other information 21 D;V Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. 13	Limitations	18		predictor, missing data).	14
190 D,V from similar studies, and other relevant evidence. 14 Implications 20 D;V Discuss the potential clinical use of the model and implications for future research. 14 Other information 21 D;V Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. 13	•	19a	-	data, and any other validation data.	
Other information Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. 13			-	from similar studies, and other relevant evidence.	
Supplementary information 21 D;V Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets. 13		20	D;V	Discuss the potential clinical use of the model and implications for future research.	14
information 21 D,V protocol, Web calculator, and data sets.		04	Dat	Provide information about the availability of supplementary resources, such as study	40
		21 22	D;V D;V		13 6

NA: not applicable

*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.